Trial Profile
A Multicentric Randomized Phase II Trial Evaluating Dual Targeting of EGFR Using the Combination of Cetuximab and Afatinib Versus Cetuximab Alone in Patients With Chemotherapy Refractory wtKRAS Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 May 2018 Status changed from active, no longer recruiting to completed.
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Sep 2013 New trial record